TABLE 1.
Clinicopathological information of PAAD patients in the training, testing, and entire cohort.
| Covariates | Entire cohort | Training cohort (n = 89) | Testing cohort (n = 88) | p-value | |
|---|---|---|---|---|---|
| Age | |||||
| <=65 | 93 (52.54%) | 51 (57.3%) | 42 (47.73%) | 0.2605 | |
| >65 | 84 (47.46%) | 38 (42.7%) | 46 (52.27%) | ||
| Gender | |||||
| Female | 80 (45.2%) | 37 (41.57%) | 43 (48.86%) | 0.4103 | |
| Male | 97 (54.8%) | 52 (58.43%) | 45 (51.14%) | ||
| Grade | |||||
| G1 | 31 (17.51%) | 17 (19.1%) | 14 (15.91%) | 0.5497 | |
| G2 | 94 (53.11%) | 51 (57.3%) | 43 (48.86%) | ||
| G3 | 48 (27.12%) | 19 (21.35%) | 29 (32.95%) | ||
| G4 | 2 (1.13%) | 1 (1.12%) | 1 (1.14%) | ||
| GX | 2 (1.13%) | 1 (1.12%) | 1 (1.14%) | ||
| Stage | |||||
| I | 21 (11.86%) | 9 (10.11%) | 12 (13.64%) | 0.6233 | |
| II | 146 (82.49%) | 73 (82.02%) | 73 (82.95%) | ||
| III | 3 (1.69%) | 2 (2.25%) | 1 (1.14%) | ||
| IV | 4 (2.26%) | 3 (3.37%) | 1 (1.14%) | ||
| Unknown | 3 (1.69%) | 2 (2.25%) | 1 (1.14%) | ||
| T stage | |||||
| T1 | 7 (3.95%) | 3 (3.37%) | 4 (4.55%) | 0.8296 | |
| T2 | 24 (13.56%) | 12 (13.48%) | 12 (13.64%) | ||
| T3 | 141 (79.66%) | 70 (78.65%) | 71 (80.68%) | ||
| T4 | 3 (1.69%) | 2 (2.25%) | 1 (1.14%) | ||
| TX | 1 (0.56%) | 1 (1.12%) | 0 (0%) | ||
| Unknown | 1 (0.56%) | 1 (1.12%) | 0 (0%) | ||
| M stage | |||||
| M0 | 79 (44.63%) | 38 (42.7%) | 41 (46.59%) | 0.5625 | |
| M1 | 4 (2.26%) | 3 (3.37%) | 1 (1.14%) | ||
| MX | 94 (53.11%) | 48 (53.93%) | 46 (52.27%) | ||
| N stage | |||||
| N0 | 49 (27.68%) | 25 (28.09%) | 24 (27.27%) | 0.6047 | |
| N1 | 123 (69.49%) | 61 (68.54%) | 62 (70.45%) | ||
| NX | 4 (2.26%) | 3 (3.37%) | 1 (1.14%) | ||
| Unknown | 1 (0.56%) | 0 (0%) | 1 (1.14%) | ||